Peer-reviewedLicence not statedJournal of Managed Care & Specialty Pharmacy
Total cost of care for long-acting injectable antipsychotics for schizophrenia: Pharmacy vs medical benefit
- 1Blue Cross Blue Shield of Michigan, Detroit
Related
- Pathways to medication adherence: a configurational analysis of psychiatric symptoms and medication attitude in patients with schizophrenia spectrum disorder receiving long-acting injectable antipsychotics.
- Perceptions of psychiatrists toward long-acting injectable antipsychotics: A cross-sectional survey from Fujian, China
- Medical Decision‐Making Capacity in Early‐Stage Alzheimer Patients: Comparison With Healthy Controls and Benefit of Assistive Information
- Conditional willingness to care for patients with Ebola virus disease: a qualitative study of risk-benefit perceptions and support needs of clinical students at a Ugandan medical school
- Comparative Effectiveness of Antidepressants and Second-Generation Antipsychotics for Agitation Among Nursing Home Residents with Dementia
BibTeX
@article{rogers2026total,
title = {{Total cost of care for long-acting injectable antipsychotics for schizophrenia: Pharmacy vs medical benefit}},
author = {Brianne Rogers and Allison Olmsted and Millie Mo},
journal = {Journal of Managed Care \& Specialty Pharmacy},
year = {2026},
month = nov,
doi = {10.18553/jmcp.2026.32.11.1386},
url = {https://doi.org/10.18553/jmcp.2026.32.11.1386},
}
RIS
TY - JOUR
TI - Total cost of care for long-acting injectable antipsychotics for schizophrenia: Pharmacy vs medical benefit
AU - Brianne Rogers
AU - Allison Olmsted
AU - Millie Mo
PY - 2026
DA - 2026/11/01
JO - Journal of Managed Care & Specialty Pharmacy
DO - 10.18553/jmcp.2026.32.11.1386
UR - https://doi.org/10.18553/jmcp.2026.32.11.1386
SN - 2376-0540
SN - 2376-1032
ER -